Opinion
Video
Multiple Myeloma Regimen Comparisons
Gabriel Hinojosa, PharmD, BCOP, reviews head-to-head comparisons in multiple myeloma regimens and evaluates efficacy and safety implications in treatment selection.
This is a video synopsis/summary of an Insights involving Gabriel Hinojosa, PharmD, BCOP.
Hinojosa discussed a rare head-to-head study comparing Dara-RVd (daratumumab [Dara], lenalidomide, bortezomib, dexamethasone) and Dara-KRd (carfilzomib, lenalidomide, dexamethasone) in transplant-eligible patients with multiple myeloma. Although initial observations favored Dara-KRd, further analysis revealed no significant difference between the 2 regimens. With both groups showing high overall response rates, the study suggests that Dara-KRd is as effective as Dara-RVd. This insight allows tailoring quadruplet therapy based on patient-specific factors. Shifting focus to patients ineligible for auto-stem cell transplants, Hinojosa highlighted the MAIA trial’s positive outcomes with Dara-RVd, showing a significant progression-free survival benefit and increased likelihood of achieving stringent complete response and measurable residual disease negativity. This prompted the use of triplet therapy for newly diagnosed transplant-ineligible patients, considering the mild adverse effects of subcutaneous daratumumab administration. Overall, these studies contribute valuable data for optimizing multiple myeloma treatment strategies.
This summary was AI-generated and reviewed by Pharmacy Times® editorial staff.
